{"protocolSection":{"identificationModule":{"nctId":"NCT06476821","orgStudyIdInfo":{"id":"CV029-1010"},"organization":{"fullName":"Bristol-Myers Squibb","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants","officialTitle":"A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-03","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2024-09-22","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-09-22","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-21","studyFirstSubmitQcDate":"2024-06-21","studyFirstPostDateStruct":{"date":"2024-06-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-21","lastUpdatePostDateStruct":{"date":"2024-06-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bristol-Myers Squibb","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics following a single oral dose of BMS-986435 in healthy adult Chinese participants."},"conditionsModule":{"conditions":["Healthy Volunteers"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":20,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1","type":"EXPERIMENTAL","interventionNames":["Drug: BMS-986435"]},{"label":"Arm 2","type":"EXPERIMENTAL","interventionNames":["Drug: BMS-986435"]}],"interventions":[{"type":"DRUG","name":"BMS-986435","description":"Specified dose on specified days","armGroupLabels":["Arm 1","Arm 2"],"otherNames":["MYK-224"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Maximum observed concentration (Cmax)","timeFrame":"Up to Day 30"},{"measure":"Time of maximum observed concentration (Tmax)","timeFrame":"Up to Day 30"},{"measure":"Area under the concentration time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))","timeFrame":"Up to Day 30"}],"secondaryOutcomes":[{"measure":"Number of participants with Adverse Events","timeFrame":"From date of written consent up to 28 days post last dose"},{"measure":"Number of participants with Serious Adverse Events","timeFrame":"From date of written consent up to 28 days post last dose"},{"measure":"Number of participants with AEs leading to discontinuation","timeFrame":"From date of written consent up to 28 days post last dose"},{"measure":"Number of participants with vital sign abnormalities","timeFrame":"Up to Day 31"},{"measure":"Number of participants with electrocardiogram (ECG) abnormalities","timeFrame":"Up to Day 31"},{"measure":"Number of participants with echocardiogram abnormalities","timeFrame":"Up to Day 30"},{"measure":"Number of participants with physical examination abnormalities","timeFrame":"Up to Day 31"},{"measure":"Number of participants with clinical laboratory abnormalities","timeFrame":"Up to Day 31"},{"measure":"Echocardiographic measures of cardiac systolic function: left ventricular ejection fraction (LVEF)","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac systolic function: left ventricular outflow tract velocity time integral (LVOT-VTI)","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac systolic function: left ventricular fractional shortening (LVFS)","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac systolic function: left ventricular global longitudinal strain (LV GLS)","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac systolic function: left ventricle stroke volume (LVSV)","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac diastolic function: lateral early diastolic mitral annular velocity (e')","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac diastolic function: septal e'","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac diastolic function: early diastolic mitral inflow velocity to early diastolic mitral annular velocity (E/e')","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac diastolic function: early diastolic mitral inflow velocity to late diastolic mitral inflow velocity ratio (E/A ratio)","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac structure: LV mass index","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac structure: LV atrial volume index","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac structure: interventricular septal thickness","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac structure: posterior wall thickness","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac structure: LV end diastolic volume","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac structure: LV end systolic volume","timeFrame":"Up to Day 30"},{"measure":"Echocardiographic measures of cardiac structure: LV end systolic volume index","timeFrame":"Up to Day 30"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Body weight of ≥ 50 kg and body mass index between 18.0 and 28.0 kg/m2, inclusive, at screening.\n* Participants must be Chinese (both biological parents are ethnically Chinese).\n* Participant has documented LVEF ≥ 60% (2D biplane Simpson's Method) at screening as determined by the echocardiographic core laboratory.\n\nExclusion Criteria:\n\n* Any acute or chronic medical illness.\n* Head injury in the last 2 years, intracranial tumor, or aneurysm.\n* History of malignancy of any type, except in situ cervical cancer \\> 5 years prior to the screening visit or surgically excised nonmelanomatous skin cancers \\> 2 years prior to the screening visit.\n* Other protocol-defined Inclusion/Exclusion criteria apply.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"BMS Study Connect Contact Center http://www.bmsstudyconnect.com/","role":"CONTACT","phone":"855-907-3286","email":"Clinical.Trials@bms.com"},{"name":"First line of the email MUST contain NCT # and Site #.","role":"CONTACT"}],"overallOfficials":[{"name":"Bristol-Myers Squibb","affiliation":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Local Institution - 0001","city":"Xuhui District","state":"Shanghai","zip":"200032","country":"China","contacts":[{"name":"Site 0001","role":"CONTACT"}]}]},"referencesModule":{"seeAlsoLinks":[{"label":"BMS Clinical Trial Information","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"},{"label":"BMS Clinical Trial Patient Recruiting","url":"https://www.BMSStudyConnect.com"},{"label":"FDA Safety Alerts and Recalls","url":"http://www.fda.gov/MEDWATCH/safety.htm"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"See plan description","accessCriteria":"See plan description","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"interventionBrowseModule":{"browseLeaves":[{"id":"M258342","name":"Sulconazole","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}